Evidence map›Paper›PMID 31379107›Full record

ArticleEMBO reports2019

Lin28 enhances de novo fatty acid synthesis to promote cancer progression via SREBP-1.

Yang Zhang, Chenchen Li, Chuanzhen Hu, Qian Wu, Yongping Cai, Songge Xing, Hui Lu, Lin Wang, De Huang, Linchong Sun and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. LIN28B/Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Yang ZhangAnhui Key Laboratory of Hepatopancreatobiliary Surgery, Department of General Surgery, Anhui Provincial Hospital, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.ORCID 0000-0001-9923-7531
Chenchen LiHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Molecular Medicine, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China.
Chuanzhen HuDepartment of Precision Machinery and Precision Instrumentation, University of Science and Technology of China, Hefei, China.
Qian WuShanghai Center for Bioinformation Technology, Shanghai, China.
Yongping CaiDepartment of Pathology, School of Medicine, Anhui Medical University, Hefei, China.
Songge XingAnhui Key Laboratory of Hepatopancreatobiliary Surgery, Department of General Surgery, Anhui Provincial Hospital, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Hui LuHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Molecular Medicine, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China.
Lin WangHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Molecular Medicine, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China.
De HuangHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Molecular Medicine, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China.
Linchong SunLaboratory of Cancer and Stem Cell Metabolism, School of Medicine, Institutes for Life Sciences, South China University of Technology, Guangzhou, China.
Tingting LiHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Molecular Medicine, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China.
Xiaoping HeHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Molecular Medicine, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, China.
Xiuying ZhongLaboratory of Cancer and Stem Cell Metabolism, School of Medicine, Institutes for Life Sciences, South China University of Technology, Guangzhou, China.
Junfeng WangHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
Ping GaoAnhui Key Laboratory of Hepatopancreatobiliary Surgery, Department of General Surgery, Anhui Provincial Hospital, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.ORCID 0000-0002-6930-7989
Zachary J SmithDepartment of Precision Machinery and Precision Instrumentation, University of Science and Technology of China, Hefei, China.
Weidong JiaAnhui Key Laboratory of Hepatopancreatobiliary Surgery, Department of General Surgery, Anhui Provincial Hospital, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.ORCID 0000-0002-2664-2031
Huafeng ZhangAnhui Key Laboratory of Hepatopancreatobiliary Surgery, Department of General Surgery, Anhui Provincial Hospital, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
University of Science and Technology of China · CNSouth China University of Technology · CNAnhui Medical University · CNChinese Academy of Sciences · CNShanghai Center For Bioinformation Technology · CN

Funding

National Basic Key Research Program of China 2014CB910600National Key R&D Program of China 2017YFA0205600National Key R&D Program of China 2018YFA0107103National Natural Science Foundation of China 31571472National Natural Science Foundation of China 81525022National Natural Science Foundation of China 81530076National Natural Science Foundation of China 81821001The Chinese Academy of Sciences XDPB10The Program of Development Foundation of Hefei Center for Physical Science and Technology 2017FXZY004
6 · The paper itself

Abstract

Lin28 plays an important role in promoting tumor development, whereas its exact functions and underlying mechanisms are largely unknown. Here, we show that both human homologs of Lin28 accelerate de novo fatty acid synthesis and promote the conversion from saturated to unsaturated fatty acids via the regulation of SREBP-1. By directly binding to the mRNAs of both SREBP-1 and SCAP, Lin28A/B enhance the translation and maturation of SREBP-1, and protect cancer cells from lipotoxicity. Lin28A/B-stimulated tumor growth is abrogated by SREBP-1 inhibition and by the impairment of the RNA binding properties of Lin28A/B, respectively. Collectively, our findings uncover that post-transcriptional regulation by Lin28A/B enhances de novo fatty acid synthesis and metabolic conversion of saturated and unsaturated fatty acids via SREBP-1, which is critical for cancer progression.

Indexed as

Disease ProgressionCell Line, TumorCell ProliferationCytoprotectionEndoplasmic Reticulum StressFatty AcidsHumansIntracellular Signaling Peptides and ProteinsLiver NeoplasmsMembrane ProteinsModels, BiologicalProtein BindingProtein BiosynthesisRNA-Binding ProteinsRNA, MessengerSterol Regulatory Element Binding Protein 1Fatty AcidsIntracellular Signaling Peptides and ProteinsLin28A protein, humanMembrane ProteinsRNA-Binding ProteinsRNA, MessengerSREBP cleavage-activating proteinSterol Regulatory Element Binding Protein 1de novo fatty acid synthesisLin28lipotoxicitysaturated and unsaturated fatty acidsSREBP-1SREBP cleavage-activating protein

Identifiers

PMID31379107
PMCPMC6776893
OpenAlexW2965455008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.